ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Leads Biolabs Receives Approval For First In Human Clinical Trials Of Lbl 034 In Relapsedrefractory Multiple Myeloma
News Feed
course image
  • Date not available
  • Admin
  • News Article

Leads Biolabs Receives Approval for First-in-Human Clinical Trials of LBL-034 in Relapsed/Refractory Multiple Myeloma

Nanjing Leads Biolabs has received approval from both the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applications for LBL-034, an innovative anti-GPRC5D/CD3 bispecific antibody designed to combat relapsed/refractory multiple myeloma.

The study design is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion trial. It aims to enrol patients who have experienced relapse or refractory cases of multiple myeloma, and who have not responded to prior treatments, including at least one proteasome inhibitor (PI), one immunomodulator (IMiD), and other standard therapies.

The primary objectives of this study is to assess the safety and tolerability of LBL-034 in the enrolled patients and to determine the recommended Phase II dose of LBL-034. Furthermore, the trial will also evaluate the efficacy of LBL-034 in treating multiple myeloma.

LBL-034, a groundbreaking pharmaceutical compound, features a distinctive molecular structure that allows for targeted binding to GPRC5D-expressing tumour cells. Its high affinity for these cells enhances its effectiveness against tumours while significantly minimising the risk of activating T-cells non-specifically. This targeted approach not only boosts the drug's anti-tumour efficacy but also reduces the potential for immunotoxicity.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form